| Market Capitalization (Millions $) |
129 |
| Shares
Outstanding (Millions) |
27 |
| Employees |
22 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-35 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Unicycive Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of various diseases. The company employs a unicyclic peptide platform technology, which allows for the design and development of novel peptide-based drugs.
Unicycive Therapeutics focuses on addressing unmet medical needs in areas such as cardiovascular diseases, oncology, and autoimmune disorders. Their research and development efforts are aimed at discovering and developing therapeutics that can effectively target specific disease mechanisms and provide improved treatment outcomes.
The company's unicyclic peptide platform technology enables the design of targeted therapies with enhanced stability, specificity, and efficacy. By combining the advantages of peptides' natural properties with the cyclic structure, Unicycive Therapeutics aims to develop drugs that can address complex biological targets.
Overall, Unicycive Therapeutics Inc is dedicated to advancing the field of therapeutics through innovative peptide-based drug development, with a focus on improving patient outcomes in a range of diseases.
Company Address: 4300 El Camino Real Los Altos 94022 CA
Company Phone Number: 351-4495 Stock Exchange / Ticker: NASDAQ UNCY
|
0.07% 